Sorrento Therapeutics, Inc.
DelistedCIK 850261fmd_1K2S4Q2ABT1BTXA8ZW5E3A4SMFManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2007 to Jun 30, 2023, 56 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 4 | 5 | 8 | 152 | 21 | 31 | 40 | 53 | 63 |
| Cost of revenue | 0 | 2 | 2 | 1 | 4 | 7 | – | – | – | – |
| Gross profit | 0 | 2 | 3 | 7 | 148 | 14 | – | – | – | – |
| Realized investment gains (losses) | – | – | – | – | – | – | 0 | 0 | (15) | (84) |
| Research and development | 6 | 0 | 24 | 45 | 26 | 11 | 107 | 111 | 207 | 221 |
| Total operating expenses | – | – | – | – | – | – | – | – | – | – |
| Operating income | (22) | (35) | (74) | (97) | 25 | (150) | (259) | (245) | (401) | (504) |
| Interest expense | 0 | 2 | 2 | 2 | 5 | 58 | 35 | 20 | 10 | 9 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | – | – |
| Income before taxes | (22) | (36) | (10) | (65) | (25) | (219) | (363) | (316) | (463) | (580) |
| Income tax expense | 0 | (2) | 36 | (1) | (36) | (6) | (0) | (2) | (34) | (2) |
| Net income from continuing operations | (22) | (35) | (46) | (64) | 11 | (213) | (363) | (314) | (429) | (578) |
| Net income | (22) | (35) | (46) | (61) | 9 | (204) | (292) | (298) | (428) | (573) |
| Net income to common shareholders | – | – | (46) | (61) | 9 | (204) | (331) | (298) | (428) | (573) |